Retrophin Inc (NASDAQ:RTRX) insider Noah L. Rosenberg sold 870 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $20.49, for a total value of $17,826.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
RTRX stock opened at $19.88 on Friday. The stock has a market capitalization of $858.02 million, a PE ratio of -9.42 and a beta of 0.86. Retrophin Inc has a 12-month low of $8.98 and a 12-month high of $21.92. The company has a current ratio of 5.97, a quick ratio of 5.88 and a debt-to-equity ratio of 0.92. The stock’s 50 day simple moving average is $19.03 and its 200 day simple moving average is $16.31.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.58). The business had revenue of $48.43 million for the quarter, compared to analysts’ expectations of $48.50 million. Retrophin had a negative return on equity of 39.84% and a negative net margin of 49.13%. On average, research analysts predict that Retrophin Inc will post -1.56 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its stake in Retrophin by 103.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,970 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,000 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Retrophin during the 4th quarter valued at $50,000. SG Americas Securities LLC purchased a new stake in Retrophin during the 1st quarter valued at $122,000. Calton & Associates Inc. purchased a new stake in Retrophin during the 1st quarter valued at $158,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Retrophin by 256.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,734 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 5,564 shares in the last quarter.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: Convertible Shares
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.